Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × gallium Ga 68 dotatate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neuroendocrine Tumors 13 Meningioma 6 Paraganglioma 5 Neuroblastoma 5 Carcinoid Tumor 5 Pheochromocytoma 4 von Hippel-Lindau Disease 3 Medulloblastoma 3 Prostatic Neoplasms 2 Oncogenic osteomalacia 2 Neuroectodermal Tumors, Primitive 2 Multiple Endocrine Neoplasia Type 1 2 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma, Neuroendocrine 2 Tumor Positron-Emission Tomography 1 Thyroid cancer, Hurthle cell 1 Thyroid Neoplasms 1 Thyroid Cancer, Papillary 1 Squamous Cell Carcinoma of Head and Neck 1 Somatostatinoma 1 Pinealoma 1 Parathyroid Neoplasms 1 Pancreatic Neoplasms 1 Optic Nerve Glioma 1 Oligodendroglioma 1 Neuroma, Acoustic 1 Neoplasms, Neuroepithelial 1 Neoplasms 1 Multiple Endocrine Neoplasia 1 Metastatic Neuroendocrine Prostate Cancer 1

Interventions

pembrolizumab 182 Gemcitabine 168 Paclitaxel 152 Carboplatin 137 Bevacizumab 128 Surveys and Questionnaires 118 Docetaxel 114 Cisplatin 114 Cyclophosphamide 109 Blood Specimen Collection 109 Exercise 107 Nivolumab 98 Fluorouracil 89 Capecitabine 86 Dexamethasone 81 Radiotherapy 80 Irinotecan 74 Pemetrexed 68 Oxaliplatin 68 Standard of Care 66 Leucovorin 64 Drug Therapy 64 Cetuximab 60 Erlotinib Hydrochloride 56 Sorafenib 53 atezolizumab 52 Ipilimumab 50 Doxorubicin 50 trametinib 47 Interviews as Topic 47

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07284589 2026-04-08

Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake

Nuclear Imaging Institute

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡